Joshua R. Clayton

Substituted 3-Imidazo[1,2-<i>a</i>]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-<i>hi</i>]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

Thomas A. Engler, James R. Henry, Sushant Malhotra et al. · Journal of Medicinal Chemistry · 2004 · 102 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F

Liandong Ma, Joshua R. Clayton, Richard A. Walgren et al. · Blood Cancer Journal · 2013 · 66 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

The development of potent and selective bisarylmaleimide GSK3 inhibitors

Thomas A. Engler, Sushant Malhotra, Timothy P. Burkholder et al. · Bioorganic & Medicinal Chemistry Letters · 2005 · 62 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

Development and a Practical Synthesis of the JAK2 Inhibitor LY2784544

David Mitchell, Kevin P. Cole, Patrick M. Pollock et al. · Organic Process Research & Development · 2011 · 53 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft model

Timothy P. Burkholder, Joshua R. Clayton, Mark E. Rempala et al. · Investigational New Drugs · 2011 · 17 citations

Medicine, Oncology, Pharmacology +15